1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 7 1.2 List of Figures 7 2 Introduction 9 2.1 Disease Introduction 10 2.2 Epidemiology 10 2.3 Symptoms 12 2.4 Etiology and Pathophysiology 13 2.4.1 Pathophysiology 14 2.5 Diagnosis 14 2.6 Prognosis 16 2.7 Treatment Options 17 2.7.1 Treatment Algorithm 17 2.7.2 Pharmacological Treatments 19 2.7.3 Non-pharmacological Treatments 21 2.7.4 Exercise 21 2.7.5 Dietary Interventions 22 3 Marketed Products 23 3.1 Overview 23 3.2 Fluarix Tetra - GlaxoSmithKline 23 3.3 FluQuadri - Sanofi Pasteur 25 3.4 Vaxigrip - Sanofi Pasteur 25 3.5 Agrippal - CSL 26 3.6 Fluad - CSL 27 3.7 Fluvax/Afluria - CSL 27 3.8 Optaflu - CSL 28 3.9 Influvac - Abbott 29 3.10 GC Flu - Green Cross Corporation 29 3.11 Intanza/IDflu - Sanofi Pasteur 30 3.12 SkyCellflu - SK Chemicals 31 3.13 Nasovac-S - Serum Institute of India 31 3.14 Comparative Efficacy and Safety of Marketed Products 32 4 Pipeline Analysis 34 4.1 Overview 34 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 35 4.3 Pipeline by Molecular Target 37 4.4 Promising Pipeline Candidates 39 4.4.1 VN-100 - Daiichi Sankyo 39 4.4.2 ASP7374 (UMN-0502) - UMN Pharma 41 4.4.3 MEDI3250 (VN-0107) - Daiichi Sankyo 43 4.5 Comparative Efficacy and Safety of Pipeline Products 45 4.6 Product Competitiveness Framework 45 5 Clinical Trial Analysis 47 5.1 Failure Rate 47 5.1.1 Overall Failure Rate 47 5.1.2 Failure Rate by Phase and Molecule Type 48 5.1.3 Failure Rate by Phase and Molecular Target 49 5.2 Clinical Trial Duration 51 5.2.1 Clinical Trial Duration by Molecule Type 51 5.2.2 Clinical Trial Duration by Molecular Target 52 5.3 Clinical Trial Size 53 5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 53 5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 55 5.4 Competitive Clinical Trials Metrics Analysis 57 6 Multi-scenario Forecast 59 6.1 Geographical Markets 59 6.2 Asia-Pacific Market 59 6.3 India 61 6.3.1 Treatment Usage Patterns 61 6.3.2 Annual Cost of Therapy 62 6.3.3 Market Size 63 6.4 China 64 6.4.1 Treatment Usage Patterns 64 6.4.2 Annual Cost of Therapy 65 6.4.3 Market Size 66 6.5 Australia 67 6.5.1 Treatment Usage Patterns 67 6.5.2 Annual Cost of Therapy 68 6.5.3 Market Size 69 6.6 South Korea 70 6.6.1 Treatment Usage Patterns 70 6.6.2 Annual Cost of Therapy 71 6.6.3 Market Size 72 6.7 Japan 73 6.7.1 Treatment Usage Patterns 73 6.7.2 Annual Cost of Therapy 74 6.7.3 Market Size 75 7 Drivers and Barriers 77 7.1 Drivers 77 7.1.1 Increasing Awareness and Affordability of Seasonal Influenza Vaccines 77 7.1.2 Launch of Quadrivalent Influenza Vaccines 77 7.1.3 Growing Elderly Population 78 7.1.4 Expansion of Cell-Cultured Vaccines 78 7.2 Barriers 78 7.2.1 Limited Awareness of Influenza’s Threat 78 7.2.2 Unpredictable Vaccine Demand 78 7.2.3 Influenza Vaccine Safety Concerns 79 7.2.4 Decentralized Vaccine Policy and Reimbursement System 79 8 Deals and Strategic Consolidations 80 8.1 Licensing Deals 80 8.1.1 Deals by Region and Value 80 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 81 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 82 8.1.4 Key Licensing Deals 85 8.2 Co-Development Deals 86 8.2.1 Deals by Region and Value 86 8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 87 8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 88 8.2.4 Key Co-Development Deals 91 9 Appendix 92 9.1 All Pipeline Drugs by Stage of Development 92 9.1.1 Discovery 92 9.1.2 Preclinical 92 9.1.3 Phase I 93 9.1.4 Phase II 94 9.1.5 Phase III 94 9.1.6 Pre-registration 95 9.2 Market Forecasts to 2022 95 9.2.1 Asia-Pacific 95 9.2.2 India 95 9.2.3 China 96 9.2.4 Australia 96 9.2.5 South Korea 97 9.2.6 Japan 97 9.3 Bibliography 98 9.4 Abbreviations 104 9.5 Research Methodology 105 9.5.1 Secondary Research 105 9.5.2 Marketed Product Profiles 105 9.5.3 Late-Stage Pipeline Candidates 105 9.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products 106 9.5.5 Product Competitiveness Framework 106 9.5.6 Pipeline Analysis 106 9.5.7 Forecasting Model 107 9.5.8 Deals Data Analysis 108 9.6 Contact Us 108 9.7 Disclaimer 108

1.1 List of Tables Table 1: Symptoms of Influenza 12 Table 2: Influenza Testing Methods 16 Table 3: Influenza Vaccination Recommendation Committees by Country 17 Table 4: Seasonal Influenza Therapeutics Market, Asia-Pacific, Most Administered Influenza Vaccines by Country 19 Table 5: Available Antiviral Drugs for Seasonal Influenza 20 Table 6: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Discovery, 2016 92 Table 7: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016 92 Table 8: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase I, 2016 93 Table 9: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase II, 2016 94 Table 10: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase III, 2016 94 Table 11: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2016 95 Table 12: Seasonal influenza Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022 95 Table 13: Seasonal Influenza Therapeutics Market, India, Market Forecast, 2015-2022 95 Table 14: Seasonal Influenza Therapeutics Market, China, Market Forecast, 2015-2022 96 Table 15: Seasonal Influenza Therapeutics Market, Australia, Market Forecast, 2015-2022 96 Table 16: Seasonal Influenza Therapeutics Market, South Korea, Market Forecast, 2015-2022 97 Table 17: Seasonal Influenza Therapeutics Market, Japan, Market Forecast, 2015-2022 97 1.2 List of Figures Figure 1: Notifications of Laboratory-Confirmed Influenza, Australia, 2012-July 2016 11 Figure 2: Seasonal Influenza Therapeutics Market, Treatment Algorithm of Seasonal Influenza 19 Figure 3: Seasonal Influenza Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Treatment of Seasonal Influenza 33 Figure 4: Pipeline for Seasonal Influenza Therapeutics by Molecular Type, Global, 2016 36 Figure 5: Pipeline for Seasonal Influenza Therapeutics by Molecular Target, Global, 2016 39 Figure 6: Seasonal Influenza Therapeutics Market, Asia-Pacific, VN-100 ($m), 2017-2022 41 Figure 7: Seasonal Influenza Therapeutics Market, Asia-Pacific, ASP7374 ($m), 2017-2022 43 Figure 8: Seasonal Influenza Therapeutics Market, Asia-Pacific, MEDI3250 ($m), 2017-2022 44 Figure 9: Seasonal Influenza Therapeutics Market, Comparative Efficacy Heatmap for Pipeline Products 45 Figure 10: Seasonal Influenza Therapeutics Market, Global, Competitor Matrix for Marketed and Pipeline Products, 2016 46 Figure 11: Seasonal Influenza Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016 48 Figure 12: Seasonal Influenza Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016 49 Figure 13: Seasonal Influenza Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016 50 Figure 14: Seasonal Influenza Therapeutics, Global, Clinical Trial Duration by Molecule Type, 2006-2016 52 Figure 15: Seasonal Influenza Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006-2016 53 Figure 16: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006-2016 54 Figure 17: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006-2016 55 Figure 18: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type, 2006-2016 56 Figure 19: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2016 57 Figure 20: Seasonal Influenza Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 58 Figure 21: Seasonal Influenza Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 58 Figure 22: Seasonal Influenza Therapeutics Market, Asia-Pacific, Treatment Patterns (million), 2015-2022 60 Figure 23: Seasonal Influenza Therapeutics Market, Asia-Pacific, Market Size ($bn), 2015-2022 61 Figure 24: Seasonal Influenza Therapeutics Market, India, Treatment Patterns (million), 2015-2022 62 Figure 25: Seasonal Influenza Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022 63 Figure 26: Seasonal Influenza Therapeutics Market, India, Market Size ($m), 2015-2022 64 Figure 27: Seasonal Influenza Therapeutics Market, China, Treatment Patterns (million), 2015-2022 65 Figure 28: Seasonal Influenza Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022 66 Figure 29: Seasonal Influenza Therapeutics Market, China, Market Size ($m), 2015-2022 67 Figure 30: Seasonal Influenza Therapeutics Market, Australia, Treatment Patterns (million), 2015-2022 68 Figure 31: Seasonal Influenza Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022 69 Figure 32: Seasonal Influenza Therapeutics Market, Australia, Market Size ($m), 2015-2022 70 Figure 33: Seasonal Influenza Therapeutics Market, South Korea, Treatment Patterns (million), 2015-2022 71 Figure 34: Seasonal Influenza Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022 72 Figure 35: Seasonal Influenza Therapeutics Market, South Korea, Market Size ($m), 2015-2022 73 Figure 36: Seasonal Influenza Therapeutics Market, Japan, Treatment Patterns (million), 2015-2022 74 Figure 37: Seasonal Influenza Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022 75 Figure 38: Seasonal Influenza Therapeutics Market, Japan, Market Size ($m), 2015-2022 76 Figure 39: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016 81 Figure 40: Seasonal Influenza Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016 82 Figure 41: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016 83 Figure 42: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016 84 Figure 43: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016 85 Figure 44: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Region, 2006-2016 87 Figure 45: Seasonal Influenza Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016 88 Figure 46: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016 89 Figure 47: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2016 90 Figure 48: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2016 90